Free tool
FAERS Monitor: Lunesta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021476 or its brand name (Lunesta, Eszopiclone). Reports on generic versions are filed under their own applications.
Reports
25,514
Serious
10,237
40% of reports
Hospitalization
4,715
Death reported
1,692
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,890
- insomnia3,913
- dysgeusia3,855
- nausea1,428
- fatigue1,239
- middle insomnia1,217
- headache1,193
- dizziness899
- somnolence895
- anxiety868
- initial insomnia857
- pain835
- diarrhoea792
- depression728
- fall681
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2,348 |
| 2006 | 4,423 |
| 2007 | 2,929 |
| 2008 | 481 |
| 2009 | 527 |
| 2010 | 726 |
| 2011 | 547 |
| 2012 | 718 |
| 2013 | 654 |
| 2014 | 659 |
| 2015 | 1,010 |
| 2016 | 1,374 |
| 2017 | 1,123 |
| 2018 | 1,232 |
| 2019 | 1,148 |
| 2020 | 1,041 |
| 2021 | 782 |
| 2022 | 823 |
| 2023 | 737 |
| 2024 | 827 |
| 2025 | 821 |
| 2026 | 584 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,028,645 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| initial insomniaSignal | 857 | 75.0 | 70.0 | 57,336 |
| middle insomniaSignal | 1,217 | 57.4 | 54.2 | 63,061 |
| dysgeusiaSignal | 3,855 | 45.1 | 43.7 | 157,990 |
| insomniaSignal | 3,913 | 12.3 | 11.9 | 40,437 |
| somnolenceSignal | 895 | 3.7 | 3.4 | 1,750 |
| drug ineffectiveSignal | 4,890 | 3.1 | 3.0 | 7,235 |
| depressionSignal | 728 | 2.6 | 2.5 | 748 |
| anxietySignal | 868 | 2.5 | 2.4 | 802 |
| fall | 681 | 1.7 | 1.6 | 193 |
| headache | 1,193 | 1.6 | 1.5 | 253 |
| nausea | 1,428 | 1.5 | 1.4 | 237 |
| dizziness | 899 | 1.5 | 1.4 | 146 |
| fatigue | 1,239 | 1.3 | 1.2 | 95 |
| pain | 835 | 1.1 | 1.0 | 11 |
| diarrhoea | 792 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.